{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:12:18Z","timestamp":1775499138411,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alkermes, Inc."},{"name":"Peloton Advantage, LLC"},{"name":"Alkermes, Inc."},{"name":"Alkermes, Inc."},{"name":"Peloton Advantage, LLC"},{"name":"Alkermes, Inc."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.pnpbp.2020.109881","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T16:02:36Z","timestamp":1580227356000},"page":"109881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT\/QTc study"],"prefix":"10.1016","volume":"100","author":[{"given":"Lei","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Yagoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narinder","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Rege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"von Moltke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje","family":"Darpo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2020.109881_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"8","key":"10.1016\/j.pnpbp.2020.109881_bb0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.21037\/atm.2018.03.17","article-title":"Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders","volume":"6","author":"Aronow","year":"2018","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.109881_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics."},{"issue":"2","key":"10.1016\/j.pnpbp.2020.109881_bb0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/jpet.118.249839","article-title":"In vitro pharmacological characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder","volume":"367","author":"Bidlack","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.pnpbp.2020.109881_bb0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.109881_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"9799","key":"10.1016\/j.pnpbp.2020.109881_bb0035","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.109881_bb0040","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.109881_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2016.08.008","article-title":"A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department","volume":"69","author":"Cole","year":"2017","journal-title":"Ann. Emerg. Med."},{"issue":"Suppl. 5","key":"10.1016\/j.pnpbp.2020.109881_bb0050","first-page":"10","article-title":"Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients","volume":"62","author":"Cutler","year":"2001","journal-title":"J. Clin. Psychiatry."},{"issue":"Suppl. 2","key":"10.1016\/j.pnpbp.2020.109881_bb0055","first-page":"35","article-title":"Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics","volume":"62","author":"Czekalla","year":"2001","journal-title":"J. Clin. Psychiatry."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.109881_bb0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4088\/JCP.v62n0310","article-title":"Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis","volume":"62","author":"Czekalla","year":"2001","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.pnpbp.2020.109881_bb0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-3-662-46943-9_17","article-title":"Clinical ECG assessment","volume":"229","author":"Darpo","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.109881_bb0070","first-page":"401","article-title":"Improving the precision of QT measurements","volume":"18","author":"Darpo","year":"2011","journal-title":"Cardiol. J."},{"key":"10.1016\/j.pnpbp.2020.109881_bb0075","author":"E14 Implementation Working Group"},{"key":"10.1016\/j.pnpbp.2020.109881_bb0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta. Med. Scand."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.109881_bb0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1542-474X.2003.08413.x","article-title":"The duration of systole in an electrocardiogram in normal humans and in patients with heart disease","volume":"8","author":"Fridericia","year":"2003","journal-title":"Ann. Noninvasive Electrocardiol."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.109881_bb0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","article-title":"Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results","volume":"17","author":"Haro","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.109881_bb0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2020.109881_bb0100","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bcpt.12336","article-title":"Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals","volume":"116","author":"Hoch","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.109881_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1710-5","article-title":"Reviewing the role of healthy volunteer studies in drug development","volume":"16","author":"Karakunnel","year":"2018","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.109881_bb0110","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9896","key":"10.1016\/j.pnpbp.2020.109881_bb0115","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.pnpbp.2020.109881_bb0120","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.pnpbp.2020.109881_bb0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","article-title":"Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia","volume":"176","author":"Martin","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2020.109881_bb0130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000338163","article-title":"The opioid system and food intake: homeostatic and hedonic mechanisms","volume":"5","author":"Nogueiras","year":"2012","journal-title":"Obes. Facts"},{"issue":"4","key":"10.1016\/j.pnpbp.2020.109881_bb0135","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5498\/wjp.v6.i4.442","article-title":"Influence of different second generation antipsychotics on the QTc interval: a pragmatic study","volume":"6","author":"Olsen","year":"2016","journal-title":"World J. Psychiatry."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.109881_bb0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/15563650.2013.862258","article-title":"Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care","volume":"52","author":"Petersen","year":"2014","journal-title":"Clin. Toxicol (Phila)."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.109881_bb0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/JCP.0000000000000320","article-title":"Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent mu-receptor antagonist","volume":"35","author":"Shram","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.109881_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.schres.2017.10.014","article-title":"A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers","volume":"195","author":"Silverman","year":"2018","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.109881_bb0155","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2018.09.002","article-title":"Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia","volume":"40","author":"Sun","year":"2018","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.109881_bb0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpdd.601","article-title":"Bioequivalence of olanzapine given in combination with samidorphan as a bilayer tablet (ALKS 3831) compared with olanzapine-alone tablets: results from a randomized, crossover relative bioavailability study","volume":"8","author":"Sun","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"2","key":"10.1016\/j.pnpbp.2020.109881_bb0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.clinthera.2014.10.001","article-title":"Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers","volume":"37","author":"Turncliff","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pnpbp.2020.109881_bb0170","author":"US Department of Health and Human Services"},{"issue":"2","key":"10.1016\/j.pnpbp.2020.109881_bb0175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00023210-200519020-00005","article-title":"Intramuscular olanzapine: a review of its use in the management of acute agitation","volume":"19","author":"Wagstaff","year":"2005","journal-title":"CNS Drugs."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.109881_bb0180","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.bmcl.2009.02.078","article-title":"Syntheses of novel high affinity ligands for opioid receptors","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.pnpbp.2020.109881_bb0185","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S0033291714001305","article-title":"A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania","volume":"45","author":"Yildiz","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2020.109881_bb0190","series-title":"[package insert]","author":"Zyprexa","year":"2018"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584619307602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584619307602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:51:23Z","timestamp":1759521083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584619307602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":38,"alternative-id":["S0278584619307602"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109881","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT\/QTc study","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109881"}}